March 28, 2024 S&P 500 Soars 10% in Q1, Outstrips Bullish Forecasts
March 20, 2024 Fed Grapples With Rate Decision Amid Inflation Concerns
March 19, 2024 Bank of Japan Ends Era of Negative Rates
Apple: AI Strategy To Help Fight DOJ, Kickstart Growth
Nvidia Stock Priced As If It Will Deliver Us The Moon
Amazon: Still Cheap Even After Robust Rally
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading
February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice
February 15, 2024 Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?
Eli Lilly and Comp. (LLY) Stock Forecast for 2024–2028. Sell or Buy?
Updated: March 28, 2024 (08:38)
Sector: HealthcareThe share price of Eli Lilly and Company (LLY) now
50/200 Day Moving Average: $725.05 / $589.55
This figure corresponds to the Average Price over the previous 50/200 days. For Eli Lilly and Comp. stocks, the 50-day moving average is the support level today.
For Eli Lilly and Comp. stocks, the 200-day moving average is the support level today.
Are you interested in Eli Lilly and Company stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Eli Lilly and Comp. stock price in 2024, 2025, 2026, 2027, 2028. How much will one Eli Lilly and Comp. share be worth in 2024 - 2028?
When should I take profit in Eli Lilly and Comp. stock? When should I record a loss on Eli Lilly and Comp. stock? What are analysts' forecasts for Eli Lilly and Comp. stock? What is the future of Eli Lilly and Comp. stock? We forecast Eli Lilly and Comp. stock performance using neural networks based on historical data on Eli Lilly and Comp. stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Eli Lilly and Comp. stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Eli Lilly and Comp. shares. This happens once a day.
Historical and forecast chart of Eli Lilly and Comp. stock
The chart below shows the historical price of Eli Lilly and Comp. stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Eli Lilly and Comp. stock price can be found in the table below.
Long-term forecasts by years.
Eli Lilly's Stock Forecast: Riding the Wave of Innovation
When it comes to assessing the future trajectory of Eli Lilly and Comp. (LLY) stock, several critical elements stand out, poised to shape its course in the near term. The blend of traditional drug revenues and the exploration of new growth markets are key factors in painting an accurate LLY stock forecast. Understanding these dynamics can offer insightful clues for those wondering whether LLY stock is a buy or sell.
Decoding Key Influencers on LLY Stock Rates
At the heart of LLY's potential for sustained growth is its robust portfolio of traditional drugs, which analysts bank on to grow impressively. This foundational strength is crucial, not just for its inherent value but for its reliability in generating a consistent cash flow. This aspect alone could be a robust argument for considering LLY a good stock to buy, thanks to its expected growth rate of 14% until the 10th year, widening to a 3% growth trajectory thereafter.
Beyond the core, the future sparkles with potential emanating from new growth markets. Eli Lilly's strategic pursuits in the obesity, Alzheimer's, psoriasis, and diabetes Type I markets could significantly elevate its stock price prediction. Analysts eyeing the LLY stock price target find these markets attractive due to their vast potential and Lilly's proactive stance, including noteworthy acquisitions, which could revolutionize its market footprint.
Understanding how these factors interplay is pivotal for any analyst aiming to craft a well-rounded Eli Lilly and Comp. stock forecast. The blending of stable growth from existing products with the explosive potential of new markets offers a compelling narrative. For investors deciphering whether to buy or sell Eli Lilly and Comp. stock, the message seems clear: the party is not over for LLY, with innovation and market expansions acting as critical levers for its future success.
- Traditional drug revenues
- New growth markets impact:
- Obesity market
- Alzheimer's market
- Psoriasis market
- Diabetes Type I market
In sum, the interplay of these factors presents a promising outlook for LLY's stock rate changes, making it an attractive option for investors seeking growth in a dynamically evolving healthcare landscape.
Review the original AnalysisUnlocking the Future: The Path to Predicting LLY Stocks
When diving into the volatile world of stock markets, one ticker that catches the eye is LLY—Eli Lilly and Comp. This pharmaceutical giant has been a hot topic among analysts, particularly due to its groundbreaking work in obesity treatment. The LLY stock forecast is a complex puzzle, intricately tied to several pivotal factors that could sway its rate in the near future.
The Blueprint to LLY's Stock Trajectory
At the forefront, the efficacy and market reception of Zepbound, Eli Lilly's flagship obesity treatment drug, plays a crucial role. Since Zepbound has already surpassed its competitors in terms of new prescriptions, its continued acceptance and success are pivotal for those considering LLY stock as a good buy. Furthermore, developments within Eli Lilly's clinical pipelines, especially the progress of orforglipron and other Phase 1 candidates, stand out as significant indicators. The impact of competition cannot be understated, with Novo Nordisk's CagriSema nipping at Zepbound's heels. This competitive landscape shapes a crucial question—is LLY stock a buy or sell?
To navigate these waters, analysts lean heavily on real-world data and clinical trial outcomes. Understanding the market's reception of Zepbound, coupled with progress in Eli Lilly’s pipeline, can guide analysts in making the most accurate LLY stock price prediction. It's a dynamic balance of forecasting the potential market shifts and weighing the competition's progress.
- Efficacy and market reception of Zepbound
- Clinical developments and pipeline progress
- Competition with Novo Nordisk and others
With these factors in play, savvy investors and analysts will find themselves in a thrilling race to predict the future of LLY stocks. Will they choose to buy, sell, or hold? Only time—and diligent analysis—will tell.
Review the original AnalysisUnraveling the Future of LLY Stock: A Predictive Guide
When it comes to forecasting the twists and turns of Eli Lilly's (LLY) stock prices, a trio of pivotal factors stand out, poised to shape the near future. Firstly, the recent retail buying and options frenzy, fueled by media hype and speculative interest, has catapulted LLY stock into the stratosphere. This surge, though thrilling, whispers warnings of a potential bubble waiting to burst. Secondly, the phenomenon of short covering, where short sellers rush to buy back shares to cover their positions, has further propelled the stock upwards. However, this movement is more reflective of a tactical retreat rather than genuine bullish sentiment. Lastly, the looming specter of valuation and overvaluation cannot be ignored. Currently standing at a towering 83x earnings, LLY's valuation significantly overshadows that of its pharmaceutical brethren, casting doubts on its sustainability.
Deciphering Stock Movements: Analysts at Work
An astute analyst would meticulously scrutinize these factors, extracting insights for precise stock movement predictions. The crux lies in balancing the heady optimism around retail buying with the hard figures of valuation. By keeping a pulse on the transition from speculative buying to potential selling, and analyzing the ripple effects of short covering, an analyst can sketch a comprehensive forecast. Equipped with a nuanced understanding of these dynamics, they can navigate the speculative ebbs and flows, steering away from the mirage of overvaluation towards more grounded predictions.
In essence, the immediate future of LLY’s stock rate is a tapestry woven from speculative fervor, forced buying actions, and valuations straining credulity. Parsing these threads could reveal the intricate patterns of future movements, presenting an analytical challenge as thrilling as it is complex.
Review the original AnalysisEli Lilly and Company is an American pharmaceutical company. It was founded in 1876 in Indianapolis, Indiana, where its headquarters are still located. It is known as the first company to start the industrial production of insulin (in 1923). The company operates in two areas: medicines for humans and veterinary medicines (a division of Elanco). The company’s products are sold in 120 countries.
Eli Lilly and Comp. daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Mar 30 | 769.78 | 757.31 | 781.56 | 3.20 |
Mar 31 | 767.47 | 760.79 | 776.45 | 2.06 |
Apr 01 | 772.77 | 766.97 | 778.56 | 1.51 |
Apr 02 | 776.94 | 771.35 | 791.16 | 2.57 |
Apr 03 | 772.74 | 760.23 | 787.35 | 3.57 |
Apr 04 | 775.99 | 768.31 | 793.68 | 3.30 |
Apr 05 | 767.84 | 754.02 | 784.66 | 4.06 |
Apr 06 | 761.62 | 754.31 | 773.73 | 2.57 |
Apr 07 | 761.17 | 748.15 | 777.38 | 3.91 |
Apr 08 | 767.79 | 753.05 | 786.21 | 4.40 |
Apr 09 | 776.77 | 758.59 | 792.85 | 4.52 |
Apr 10 | 795.41 | 783.96 | 812.12 | 3.59 |
Apr 11 | 795.41 | 789.45 | 809.02 | 2.48 |
Apr 12 | 796.61 | 785.61 | 801.86 | 2.07 |
Apr 13 | 811.18 | 806.07 | 826.52 | 2.54 |
Apr 14 | 819.46 | 805.69 | 828.31 | 2.81 |
Apr 15 | 834.70 | 817.92 | 848.22 | 3.70 |
Apr 16 | 829.94 | 815.00 | 840.15 | 3.09 |
Apr 17 | 813.76 | 801.31 | 829.87 | 3.56 |
Apr 18 | 818.40 | 800.47 | 830.67 | 3.77 |
Apr 19 | 819.38 | 803.89 | 829.46 | 3.18 |
Apr 20 | 828.47 | 811.82 | 836.43 | 3.03 |
Apr 21 | 846.62 | 836.71 | 858.30 | 2.58 |
Apr 22 | 837.47 | 830.44 | 854.56 | 2.90 |
Apr 23 | 850.29 | 841.36 | 856.92 | 1.85 |
Apr 24 | 839.57 | 824.71 | 853.18 | 3.45 |
Apr 25 | 826.48 | 813.34 | 841.11 | 3.41 |
Apr 26 | 827.96 | 814.30 | 836.66 | 2.75 |
Apr 27 | 817.04 | 803.31 | 822.43 | 2.38 |
Apr 28 | 806.01 | 794.64 | 821.72 | 3.41 |
Eli Lilly and Comp. Daily Price Targets
Eli Lilly and Comp. Stock Forecast 03-30-2024.
Forecast target price for 03-30-2024: $769.78.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.103%.
Pessimistic target level: 757.31
Optimistic target level: 781.56
Eli Lilly and Comp. Stock Forecast 03-31-2024.
Forecast target price for 03-31-2024: $767.47.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 2.016%.
Pessimistic target level: 760.79
Optimistic target level: 776.45
Eli Lilly and Comp. Stock Forecast 04-01-2024.
Forecast target price for 04-01-2024: $772.77.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 1.489%.
Pessimistic target level: 766.97
Optimistic target level: 778.56
Eli Lilly and Comp. Stock Forecast 04-02-2024.
Forecast target price for 04-02-2024: $776.94.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 2.504%.
Pessimistic target level: 771.35
Optimistic target level: 791.16
Eli Lilly and Comp. Stock Forecast 04-03-2024.
Forecast target price for 04-03-2024: $772.74.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.445%.
Pessimistic target level: 760.23
Optimistic target level: 787.35
Eli Lilly and Comp. Stock Forecast 04-04-2024.
Forecast target price for 04-04-2024: $775.99.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.197%.
Pessimistic target level: 768.31
Optimistic target level: 793.68
LLY (LLY) Monthly Stock Prediction for 2024
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Apr. | 818.65 | 739.89 | 864.41 | 14.40 |
May. | 793.10 | 715.78 | 815.79 | 12.26 |
Jun. | 748.77 | 700.10 | 788.68 | 11.23 |
Jul. | 780.89 | 718.97 | 813.38 | 11.61 |
Aug. | 698.66 | 642.35 | 726.82 | 11.62 |
Sep. | 662.33 | 637.36 | 712.27 | 10.52 |
Oct. | 692.47 | 632.16 | 748.28 | 15.52 |
Nov. | 736.58 | 687.74 | 800.74 | 14.11 |
Dec. | 779.67 | 728.99 | 800.95 | 8.98 |
Eli Lilly and Comp. forecast for this year
Eli Lilly and Comp. Stock Prediction for Apr 2024
An uptrend is forecast for this month with an optimal target price of $818.645. Pessimistic: $739.89. Optimistic: $864.41
Eli Lilly and Comp. Stock Prediction for May 2024
An downtrend is forecast for this month with an optimal target price of $793.104. Pessimistic: $715.78. Optimistic: $815.79
Eli Lilly and Comp. Stock Prediction for Jun 2024
An downtrend is forecast for this month with an optimal target price of $748.769. Pessimistic: $700.10. Optimistic: $788.68
Eli Lilly and Comp. Stock Prediction for Jul 2024
An uptrend is forecast for this month with an optimal target price of $780.891. Pessimistic: $718.97. Optimistic: $813.38
Eli Lilly and Comp. Stock Prediction for Aug 2024
An downtrend is forecast for this month with an optimal target price of $698.663. Pessimistic: $642.35. Optimistic: $726.82
Eli Lilly and Comp. Stock Prediction for Sep 2024
An downtrend is forecast for this month with an optimal target price of $662.333. Pessimistic: $637.36. Optimistic: $712.27
Eli Lilly and Comp. Stock Prediction for Oct 2024
An uptrend is forecast for this month with an optimal target price of $692.469. Pessimistic: $632.16. Optimistic: $748.28
Eli Lilly and Comp. Stock Prediction for Nov 2024
An uptrend is forecast for this month with an optimal target price of $736.579. Pessimistic: $687.74. Optimistic: $800.74
Eli Lilly and Comp. Stock Prediction for Dec 2024
An uptrend is forecast for this month with an optimal target price of $779.669. Pessimistic: $728.99. Optimistic: $800.95
Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 678.31 | 639.51 | 703.89 | 9.15 |
Feb | 670.38 | 647.72 | 691.29 | 6.30 |
Mar | 664.28 | 612.46 | 683.27 | 10.36 |
Apr | 638.37 | 600.19 | 658.29 | 8.82 |
May | 675.71 | 630.04 | 694.16 | 9.24 |
Jun | 653.75 | 634.21 | 675.85 | 6.16 |
Jul | 711.54 | 644.94 | 752.25 | 14.26 |
Aug | 701.37 | 682.22 | 746.96 | 8.67 |
Sep | 678.58 | 611.53 | 703.28 | 13.05 |
Oct | 667.11 | 619.41 | 691.39 | 10.41 |
Nov | 657.57 | 600.29 | 705.44 | 14.90 |
Dec | 628.50 | 609.71 | 657.92 | 7.33 |
Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 661.19 | 628.52 | 716.20 | 12.24 |
Feb | 613.91 | 587.57 | 631.47 | 6.95 |
Mar | 692.12 | 652.53 | 741.61 | 12.01 |
Apr | 693.02 | 641.67 | 734.47 | 12.63 |
May | 650.68 | 583.85 | 710.74 | 17.85 |
Jun | 629.53 | 595.16 | 672.09 | 11.45 |
Jul | 648.35 | 585.14 | 709.88 | 17.57 |
Aug | 594.41 | 557.32 | 613.73 | 9.19 |
Sep | 524.09 | 496.16 | 567.02 | 12.50 |
Oct | 556.12 | 539.49 | 573.47 | 5.93 |
Nov | 553.22 | 517.98 | 605.72 | 14.49 |
Dec | 544.59 | 498.57 | 559.46 | 10.88 |
Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 533.27 | 491.67 | 551.98 | 10.93 |
Feb | 525.64 | 479.86 | 579.62 | 17.21 |
Mar | 524.27 | 504.51 | 567.89 | 11.16 |
Apr | 567.21 | 545.83 | 620.30 | 12.01 |
May | 605.55 | 578.79 | 628.38 | 7.89 |
Jun | 585.09 | 526.52 | 620.07 | 15.09 |
Jul | 621.60 | 597.35 | 640.99 | 6.81 |
Aug | 630.48 | 595.24 | 694.42 | 14.28 |
Sep | 630.48 | 592.78 | 659.99 | 10.18 |
Oct | 670.65 | 629.67 | 704.65 | 10.64 |
Nov | 634.03 | 602.71 | 660.41 | 8.74 |
Dec | 602.71 | 562.75 | 623.86 | 9.80 |
Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2028
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 590.17 | 541.07 | 610.12 | 11.32 |
Feb | 577.90 | 555.36 | 628.23 | 11.60 |
Mar | 583.91 | 557.34 | 620.34 | 10.16 |
Apr | 567.21 | 522.96 | 594.49 | 12.03 |
May | 617.35 | 584.44 | 642.23 | 9.00 |
Jun | 677.54 | 624.69 | 713.65 | 12.47 |
Jul | 683.71 | 664.15 | 733.48 | 9.45 |
Aug | 650.82 | 615.28 | 671.97 | 8.44 |
Sep | 625.44 | 596.17 | 656.33 | 9.17 |
Oct | 631.94 | 574.43 | 658.23 | 12.73 |
Nov | 637.69 | 574.69 | 676.66 | 15.07 |
Dec | 686.60 | 666.07 | 727.66 | 8.46 |
Eli Lilly and Comp. information and performance
LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN, US
Market capitalization of the Eli Lilly and Company is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of LLY shares in the company outstanding by the market price of one share.
EBITDA of Eli Lilly and Comp. is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Eli Lilly and Comp. (LLY) stock dividend
Eli Lilly and Comp. last paid dividends on 02/14/2024. The next scheduled payment will be on 03/08/2024. The amount of dividends is $4.52 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.